˙
C. IBIS¸ ET AL.
972
(SCH2), 52.6 (NCH2), 65.4 (OCH2), 108.8, 118.1, 124.2, 150.6 (Cbutadien). MS (+ESI):
m/z 489.84 [M+Na]+. C19H23Cl3N2O3S (465.82), calcd. C, 48.99; H, 4.98; S, 6.88; N,
6.01; found C, 49.12; H, 4.59; S, 6.59; N, 6.11.
1-Morpholino-2-nitro-1-(2,3,5,6-tetrafluorophenylthio)-3,4,4-trichloro-1,3-
butadiene (6b): Compound 6b was synthesized from 3b (0.1 g, 0.24 mmol) and 5 (0.021
g, 0.24 mmol) according to the general procedure 2. Yellow crystals. Yield: 0.097 g (86%).
M.p.: 172.0–173.0 ◦C. Rf 0.40 (CH2Cl2). IR: 3058 (C-Harom.), 2856, 2985 (C-Haliph.), 1587,
1621 (C C), 1276, 1537 (NO2). 1H NMR: 3.28–3.44 (bs, 2H, CH2morph.), 3.57–3.71 (bs,
4H, CH2morph.), 3.72–3.85 (bs, 2H, CH2morph.), 7.11–7.18 (m, 1H, Harom.). 13C NMR: 52.7
(NCH2), 65.2 (OCH2), 107.5–107.8 (t, CHarom.), 109.2–109.5 (t, SCarom.), 120.4, 123.9,
126.1, 161.3 (Cbutadien). MS (+ESI): m/z 490.80 [M+Na]+. C14H9Cl3F4N2O3S (467.65),
calcd. C, 35.96; H, 1.94; S, 6.86; N, 5.99; found C, 35.46; H, 1.86; S, 7.28; N, 5.96.
1-[(2-Fluorophenyl)piperazinyl]-2-nitro-1-[(4-tert-butylbenzyl)thio]-3,4,4-
trichloro-1,3-butadiene (8a): Compound 8a was synthesized from 3a (0.1 g, 0.24 mmol)
and 7a (0.04 g, 0.24 mmol) according to the general procedure 2. Yellow crystals. Yield:
0.113 g (83%). M.p.: 160.0–160.3 ◦C. Rf 0.53 (CH2Cl2). IR: 3054 (C-Harom), 2862, 2961
1
(C-Haliph.), 1586, 1611 (C C), 1275, 1540 (NO2). H NMR: 1.24 (s, 9H, CH3), 3.12 (s,
4H, CH2piper), 3.45–3.92 (bs, 4H, CH2piper), 4.12 (s, 2H, SCH2), 6.82–6.86 (t, 1H, Harom),
6.91-7.02 (m, 3H, Harom.), 7.13–7.15 (d, J = 8.3 Hz, 2H, Harom.), 7.28–7.31 ppm (d, J =
8.3 Hz, 2H, Harom.), 2). 13C NMR: 30.2 (CH3), 33.6 (Cq-t-butyl), 38.9 (SCH2), 49.4, 52.3
(NCH2), 115.4, 115.5, 124.1, 150.5 (Cbutad.), 153.7, 155.7 (F-Carom.). MS (+ESI): m/z
582.63 [M+Na]+. C25H27Cl3FN3O2S (558.92), calcd. C, 53.72; H, 4.87; S, 5.74; N, 7.52;
found C, 53.34; H, 4.80; S, 6.12; N, 7.99.
1-[(4-Fluorophenyl)piperazinyl]-2-nitro-1-[(4-tert-butylbenzyl)thio]-3,4,4-
trichloro-1,3-butadiene (8b): Compound 8b was synthesized from 3a (0.1 g, 0.24 mmol)
and 7b (0.04 g, 0.24 mmol) according to the general procedure 2. Red crystals. Yield:
0.115 g (86%). M.p.: 176.4–177.0 ◦C. Rf 0.50 (CH2Cl2). IR: 3028, 3063 (C-Harom.), 2868,
2966 (C-Haliph.), 1588, 1607 (C C), 1269, 1538 (NO2). 1H NMR: 1.24 (s, 9H, CH3), 3.12
(s, 4H, CH2piper.), 3.48–3.79 (bs, 4H, CH2piper.), 4.12 (s, 2H, SCH2), 6.78–6.81 (m, 2H,
Harom.), 6.89–6.93 (t, 2H, Harom.), 7.13–7.15 (d, J = 8.3 Hz, 2H, Harom.), 7.29–7.30 (d, J
= 8.3 Hz, 2H, Harom.). 13C NMR: 30.3 (CH3), 33.6 (Cq-t-butyl), 38.9 (SCH2), 49.5, 52.0
(NCH2), 124.2, 128.1, 145.6, 150.6 (Cbutadien), 157.9, 156.0 (F-Carom.). MS (+ESI): m/z
582.48 [M+Na]+. C25H27Cl3FN3O2S (558.92), calcd. C, 53.72; H, 4.87; S, 5.74; N, 7.52;
found C, 53.98; H, 5.00; S, 7.45; N, 7.39.
1-(N-Methylpiperazinyl)-2-nitro-1-[(4-tert-butylbenzyl)thio]-3,4,4-trichloro-1,
3-butadiene (8c): Compound 8c was synthesized from 3a (0.1 g, 0.24 mmol) and 7c
(0.024 g, 0.24 mmol) according to the general procedure 2. Yellow crystals. Yield: 0.08
g (69%). M.p.: 125.4–126.3 ◦C. Rf 0.60 (MeOH). IR: 3026, 3054 C-Harom.), 2801, 2870,
1
2966 (C-Haliph.), 1591 (C C), 1275, 1534 (NO2). H NMR: 1.24 (s, 9H, CH3), 2.25 (s,
3H, NCH3), 2.44 (s, 4H, CH2 piperazine), 3.36–3.68 (bs, 4H, CH2piper.), 4.09 (s, 2H, SCH2),
7.12–7.13 (d, J = 8.3 Hz, 2H, Harom.), 7.28–7.29 ppm (d, J = 8.3 Hz, 2H, Harom.). 13C
NMR: 26.2, 26.4 ppm (CH3), 29.7 (NCH3), 34.9 (Cq-t-butyl), 40.6, 40.7 (SCH2), 48.2,
49.7 (NCH2), 113.8, 119.94, 146.5, 162.9 (Cbutadiene). MS (+ESI): m/z 478.35 [M]+.
C20H26Cl3N3O2S (478.86), calcd. C, 50.16; H, 5.47; S, 6.70; N, 8.77; found C, 50.22; H,
5.11; S, 7.22; N, 8.46.
1-[(2-Fluorophenyl)piperazinyl]-2-nitro-1-(2,3,5,6-tetrafluorophenylthio)-3,4,4-
trichloro-1,3-butadien (8d): Compound 8d was synthesized from 3b (0.1 g, 0.24 mmol)
and 7a (0.04 g, 0.24 mmol) according to the general procedure 2. Orange single crystals